Optimizing lithium treatment in bipolar disorder: A review of the literature and clinical recommendations

Journal of Psychiatric Practice

Volumn 9, Issue 5, 2003, Pages 333-343

  Goodwin, Frederick K ^a   Goldstein, Mark A ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Bipolar disorder; Carbamazepine; Divalproex; Lamotrigine; Lithium; Mood stabilizers; Rapid cycling

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; DIAZEPAM; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOXETINE; FOLIC ACID; ISOTRETINOIN; LAMOTRIGINE; LITHIUM; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PHENOBARBITAL; THIAZIDE DIURETIC AGENT; VALPROATE SEMISODIUM; VITAMIN B GROUP; XANTHINE DERIVATIVE;

ACNE; AMNESIA; BIPOLAR DISORDER; BLOOD TOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTINUING EDUCATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; FEMALE; GAIT DISORDER; HUMAN; HYPOTHYROIDISM; IRRITABILITY; KIDNEY DISEASE; LITERATURE; LIVER TOXICITY; MALE; MEDICAL EDUCATION; MEMORY DISORDER; META ANALYSIS; NEPHROGENIC DIABETES INSIPIDUS; NEUROLOGIC DISEASE; OVARY POLYCYSTIC DISEASE; PANCREAS DISEASE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RESIDENCY EDUCATION; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; SLURRED SPEECH; SUICIDE; WEIGHT GAIN;

EID: 0141841802     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200309000-00002     Document Type: Review

References (80)

1. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994;31:91-6.
2. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-28.
3. Weissman MM, Bruce ML, Leaf PJ, et al. Affective disorders. In: Robins LN, Regier DA, eds. Psychiatric disorders in America: The Epidemiological Catchment Area study. New York: Macmillan; 1991.
4. Tsuang MT, Winokur G, Crowe RR. Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions. Br J Psychiatry 1980;137:497-504.
5. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-24.
6. Swann AC, Bowden CL, Morris D, et al. Depression during mania: Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37-42.
7. Duffy A, Alda M, Kutcher S, et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry 2002;63:1171-8.
8. Passmore MF, Garnham J, Duffy A, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003;5:110-4.
9. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470-8.
10. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders-a randomised study. J Affect Disord 1997;43:151-61.
11. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204.
12. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114-8.
13. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999;14:283-5.
14. Baldessarini RJ, Tondo L, Hennen J, et al. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002;10:59-75.
15. Lim PZ, Tunis SL, Edell WS, et al. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: Adherence to published practice guidelines. Bipolar Disord 2001;3:165-73.
16. Dunner DL, Dwyer T, Fieve R. Depressive symptoms in patients with unipolar and bipolar affective disorder. Compr Psychiatry 1976;17:447-51.
17. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
18. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400.
19. Yatham LN, Behnke K, Timotijevic I, et al. Placebo-controlled 18-month trial of lamotrigine maintenance treatment in recently depressed patients with bipolar I disorder. CINP Poster Abstract. Montreal, Quebec, July 2002.
20. Calabrese JR, Soegaard J, Hompland M, et al. Summary and meta-analysis of two large placebo-controlled 18-month maintenance trials of lamotrigine and lithium treatment in bipolar I disorder. Int J Neuropsychopharmacol 2002;5:S58.
21. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand 2001;104:163-72.
22. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998;59:405-14.
23. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: Data from a randomized prospective trial. Pharmacopsychiatry 1996;29:103-7.
24. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: Update and new findings. J Clin Psychiatry 2003;64(Suppl 5):44-52.
25. Brodersen A, Licht RW, Vestergaard P, et al. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000;176:429-33.
26. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003 (in press)
27. Ahrens B, Grof P, Moller HJ, et al. Extended survival of patients on long-term lithium treatment. Can J Psychiatry 1995;40:241-6.
28. Kallner G, Lindelius R, Petterson U, et al. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000;33:8-13.
29. Wolff J. The endocrine effects of lithium. In: Boissier JR, Hippius H, Pichot P, eds. Proceedings of the IX Congress of the Collegium Internationale Neuropsychopharmacologicum. New York: Elsevier; 1974:621-8.
30. Mannisto PT. Endocrine side-effects of lithium. In: Johnson FN, ed. Handbook of lithium therapy. Baltimore: University Park Press; 1980:310-22.
31. Yassa R, Saunders A, Nastase C, et al. Lithium-induced thyroid disorders: A prevalence study. J Clin Psychiatry 1988;49:14-6.
32. Hatterer JA, Kocsis JH, Stokes PE. Thyroid function in patients maintained on lithium. Psychiatry Res 1988;26:249-57.
33. Kilzieh N, Akiskal HS. Rapid-cycling bipolar disorder: An overview of research and clinical experience. Psychiatr Clin North Am 1999;22:585-607.
34. Bocchetta A, Mossa P, Velluzzi F, et al. Ten-year follow-up of thyroid function in lithium patients. J Clin Psychopharmacol 2001;21:594-8.
35. Kirov G. Thyroid disorders in lithium-treated patients. J Affect Disord 1998;50:33-40.
36. Kusalic M. Grade II and grade III hypothyroidism in rapid-cycling bipolar patients. Neuropsychobiology 1992;25:177-81.
37. Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001;2:59-69.
38. Bakker JB, Pepplinkhuizen L. Cutaneous side effects of lithium. In: Johnson FN, ed. Handbook of lithium therapy. Baltimore: University Park Press; 1980:372-7.
39. Sarantidis D, Waters B. A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry 1983;143:42-50.
40. Chan HH, Wing Y, Su R, et al. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord 2000;57:107-13.
41. Goodwin FK, Jamison KR. Manic depressive illness. New York: Oxford University Press; 1990.
42. Schou M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984;70:594-602.
43. Judd LL, Squire LR, Butters N, et al. Effects of psychotropic drugs on cognition and memory in normal humans and animals. In: Meltzer HY, ed. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987:1467-75.
44. Jefferson JW, Greist JH, Ackerman DL, et al. Lithium encyclopedia for clinical practice. 2nd ed. Washington, DC: American Psychiatric Press; 1987.
45. Honig A, Arts BM, Ponds RW, et al. Lithium induced cognitive side-effects in bipolar disorder: A qualitative analysis and implications for daily practice. Int Clin Psychopharmacol. 1999;14:167-71.
46. Stip E, Dufresne J, Lussier I, et al. A double-blind, placebo-controlled study of the effects of lithium on cognition in healthy subjects: Mild and selective effects on learning. J Affect Disord 2000;60:147-57.
47. Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology 1995;45:1494-9.
48. Bendz H, Aurell M, Balldin J, et al. Kidney damage in long-term lithium patients: A cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994;9:1250-4.
49. Bendz H, Aurell M, Lanke J. A historical cohort study of kidney damage in long-term lithium patients: Continued surveillance needed. Eur Psychiatry 2001;16:199-206.
50. Coskunol H, Vahip S, Mees ED, et al. Renal side-effects of long-term lithium treatment. J Affect Disord 1997;43:5-10.
51. Turan T, Esel E, Tokgoz B, et al. Effects of short- and long-term lithium treatment on kidney functioning in patients with bipolar mood disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:561-5.
52. Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: A progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000;11:1439-48.
53. Bendz H, Aurell M. Drug-induced diabetes insipidus: Incidence, prevention and management. Drug Saf 1999;21:449-56.
54. Chugh S, Yager H. End-stage renal disease after treatment with lithium. J Clin Psychopharmacol 1997;17:495-7.
55. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-8.
56. Crowe AV, Howse M, Bell GM, et al. Substance abuse and the kidney. QJM 2000;93:147-52.
57. Norris KC, Thornhill-Joynes M, Tareen N. Cocaine use and chronic renal failure. Semin Nephrol 2001;21:362-6.
58. Perneger TV, Whelton PK, Puddey IB, et al. Risk of end-stage renal disease associated with alcohol consumption. Am J Epidemiol 1999;150:1275-81.
59. Peselow ED, Dunner DL, Fieve RR, et al. Lithium carbonate and weight gain. J Affect Disord 1980;2:303-10.
60. Fagiolini A, Frank E, Houck PR, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002;63:528-33.
61. Chengappa KN, Chalasani L, Brar JS, et al. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: An open-label, nonrandomized chart review. Clin Ther 2002:24:1576-84.
62. Fagiolini, A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003;160:112-7.
63. Vendsborg PB, Bech P, Rafaelsen OJ, et al. Lithium treatment and weight gain. Acta Psychiatr Scand 1976;53:139-47.
64. Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486-91.
65. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
66. Li R, El-Mallahk RS. A novel evidence of different mechanisms of lithium and valproate neuroprotective action on human SY5Y neuroblastoma cells: Caspase-3 dependency. Neurosci Lett 2000;294:147-50.
67. Chen B, Wang JF, Hill BC, et al. Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos. Brain Res Mol Brain Res 1999;70:45-53.
68. Keck PE Jr, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997;33:87-91.
69. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-9.
70. Vieta E, Reinares M, Corbella B, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001;21:469-73.
71. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-25.
72. Tohen M, Chengappa KNR, Suppes T, et al. Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: An 18-month study. Montreal, Canada: CINP, July 2002.
73. Yatham LN, Binder C, Riccardelli R, et al. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol. 2003;18:227-35.
74. Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: An open 6-month study. J Affect Disord 2001;67:213-9.
75. Grof P, MacCrimmon D, Saxena B, et al. Bioavailabilty and side effects of different lithium carbonate products. Neuropsychobiology 1976;2:313-23.
76. Kusalic M, Engelsmann F. Renal reactions to changes of lithium dosage. Neuropsychobiology 1996;34:113-6.
77. Hetmar O, Povlsen UJ, Ladefoged J, et al. Lithium: Long-term effects on the kidney: A prospective follow-up study ten years after kidney biopsy. Br J Psychiatry 1991;158:53-8.
78. O'Donovan C, Hawkes J, Bowen R. Effect of lithium dosing schedule on urinary output. Acta Psychiatr Scand 1993;87:92-5.
79. Movig KL, Baumgarten R, Leufkens HG, et al. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry 2003;182:319-23.
80. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: Managing the chaos of bipolar disorder. Biol Psychiatry 2000;48:593-604.